Current Edition

Early Interventions to Reduce the Impact of Immunogenicity on the Development of Biopharmaceuticals

The development of biological therapeutics has led to
remarkable clinical benefits in many indications. But,
despite this success, the induction of anti-drug antibodies
(ADAs) due to the potential immunogenicity of these
therapeutics, remains a significant challenge to the
successful development of biotherapeutics. In their paper,
Dr Karen Hill and Dr Gary Bembridge of Abzena discuss the
impact of immunogenicity and approaches that can be
taken in pre-clinical development to reduce the effect on
product success and patient experience.